• Je něco špatně v tomto záznamu ?

Fluorochrome choices for multi-color flow cytometry

J. Flores-Montero, T. Kalina, A. Corral-Mateos, L. Sanoja-Flores, M. Pérez-Andrés, M. Martin-Ayuso, L. Sedek, K. Rejlova, A. Mayado, P. Fernández, V. van der Velden, S. Bottcher, JJM. van Dongen, A. Orfao,

. 2019 ; 475 (-) : 112618. [pub] 20190607

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20023411

Fluorochrome selection is a key step in designing multi-color antibody panels. The list of available fluorochromes is continuously growing, fitting current needs in clinical flow cytometry to simultaneously use more markers to better define multiple leukocyte subpopulations in a single tube. Several criteria guide fluorochrome selection: i) the fluorescence profiles (excitation and emission), ii) relative brightness, iii) fluorescence overlap, iv) fluorochrome stability, and v) reproducible conjugation to antibodies. Here we used 75 samples (45 bone marrow and 30 blood) to illustrate EuroFlow strategies for evaluation of compatible fluorochromes, and how the results obtained guide fluorochrome selection as a critical step in the antibody-panel building process. Our results allowed identification of optimal fluorescence profiles (e.g. higher fluorescence intensity and/or resolution with limited fluorescence overlap into neighbor channels) for brilliant violet (BV)421 and BV510 in the violet laser and allophycocyanin (APC) hilite 7 (H7) or APC C750 in the red laser vs. other candidate fluorochromes generally applied for the same detectors and here evaluated. Moreover, evaluation of the same characteristics for another group of fluorochromes (e.g. BV605, BV650, PE CF594, AF700 or APC AF700) guided selection of the most appropriate fluorochrome conjugates to be combined in a multi-color antibody panel. Albeit this is a demanding approach, it could be successfully applied for selection of fluorochrome combinations for the EuroFlow antibody panels for diagnosis, classification and monitoring of hematological malignancies and primary immunodeficiencies. Consequently, sets of 8-, 10- and 12-color fluorochrome combinations are proposed as frame of reference for initial antibody panel design.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023411
003      
CZ-PrNML
005      
20250108120326.0
007      
ta
008      
201125e20190607ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jim.2019.06.009 $2 doi
035    __
$a (PubMed)31181212
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Flores-Montero, Juan $u Cancer Research Center (IBMCC-CSIC/USAL-IBSAL), Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca, Salamanca, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBER-ONC) CB16/12/00400, Instituto de Salud Carlos III, Madrid, Spain.
245    10
$a Fluorochrome choices for multi-color flow cytometry / $c J. Flores-Montero, T. Kalina, A. Corral-Mateos, L. Sanoja-Flores, M. Pérez-Andrés, M. Martin-Ayuso, L. Sedek, K. Rejlova, A. Mayado, P. Fernández, V. van der Velden, S. Bottcher, JJM. van Dongen, A. Orfao,
520    9_
$a Fluorochrome selection is a key step in designing multi-color antibody panels. The list of available fluorochromes is continuously growing, fitting current needs in clinical flow cytometry to simultaneously use more markers to better define multiple leukocyte subpopulations in a single tube. Several criteria guide fluorochrome selection: i) the fluorescence profiles (excitation and emission), ii) relative brightness, iii) fluorescence overlap, iv) fluorochrome stability, and v) reproducible conjugation to antibodies. Here we used 75 samples (45 bone marrow and 30 blood) to illustrate EuroFlow strategies for evaluation of compatible fluorochromes, and how the results obtained guide fluorochrome selection as a critical step in the antibody-panel building process. Our results allowed identification of optimal fluorescence profiles (e.g. higher fluorescence intensity and/or resolution with limited fluorescence overlap into neighbor channels) for brilliant violet (BV)421 and BV510 in the violet laser and allophycocyanin (APC) hilite 7 (H7) or APC C750 in the red laser vs. other candidate fluorochromes generally applied for the same detectors and here evaluated. Moreover, evaluation of the same characteristics for another group of fluorochromes (e.g. BV605, BV650, PE CF594, AF700 or APC AF700) guided selection of the most appropriate fluorochrome conjugates to be combined in a multi-color antibody panel. Albeit this is a demanding approach, it could be successfully applied for selection of fluorochrome combinations for the EuroFlow antibody panels for diagnosis, classification and monitoring of hematological malignancies and primary immunodeficiencies. Consequently, sets of 8-, 10- and 12-color fluorochrome combinations are proposed as frame of reference for initial antibody panel design.
650    _2
$a průtoková cytometrie $x metody $7 D005434
650    12
$a fluorescenční barviva $7 D005456
650    _2
$a lidé $7 D006801
650    _2
$a imunofenotypizace $x metody $7 D016130
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kalina, Tomas $u CLIP Cytometry, Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Corral-Mateos, Alba $u Cancer Research Center (IBMCC-CSIC/USAL-IBSAL), Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca, Salamanca, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBER-ONC) CB16/12/00400, Instituto de Salud Carlos III, Madrid, Spain.
700    1_
$a Sanoja-Flores, Luzalba $u Cancer Research Center (IBMCC-CSIC/USAL-IBSAL), Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca, Salamanca, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBER-ONC) CB16/12/00400, Instituto de Salud Carlos III, Madrid, Spain.
700    1_
$a Pérez-Andrés, Martin $u Cancer Research Center (IBMCC-CSIC/USAL-IBSAL), Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca, Salamanca, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBER-ONC) CB16/12/00400, Instituto de Salud Carlos III, Madrid, Spain.
700    1_
$a Martin-Ayuso, Marta $u Cytognos SL, Salamanca, Spain.
700    1_
$a Sedek, Lukasz $u Department of Pediatric Hematology and Oncology, Medical University of Silesia in Katowice, Zabrze, Poland.
700    1_
$a Rejlova, Katerina $u CLIP Cytometry, Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Mayado, Andrea $u Cancer Research Center (IBMCC-CSIC/USAL-IBSAL), Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca, Salamanca, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBER-ONC) CB16/12/00400, Instituto de Salud Carlos III, Madrid, Spain.
700    1_
$a Fernández, Paula $u FACS/Stem cell Laboratory, Institute of Laboratory Medicine, Kantonsspital Aarau AG, Aarau, Switzerland.
700    1_
$a van der Velden, Vincent $u Department of Immunology, Erasmus MC, Erasmus University Medical Center, Rotterdam, the Netherlands.
700    1_
$a Böttcher, Sebastian, $d 1971- $u Rostock University Medical Center, Division of Internal Medicine, Medical Clinic III, Hematology, Oncology and Palliative Medicine, Special Hematology Laboratory, Rostock, Germany. $7 xx0327357
700    1_
$a van Dongen, Jaques J M $u Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands. Electronic address: J.J.M.van_Dongen@lumc.nl.
700    1_
$a Orfao, Alberto $u Cancer Research Center (IBMCC-CSIC/USAL-IBSAL), Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca, Salamanca, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBER-ONC) CB16/12/00400, Instituto de Salud Carlos III, Madrid, Spain.. Electronic address: orfao@usal.es.
773    0_
$w MED00010028 $t Journal of immunological methods $x 1872-7905 $g Roč. 475 (20190607), s. 112618
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31181212 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20250108120321 $b ABA008
999    __
$a ok $b bmc $g 1595730 $s 1114087
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 475 $c - $d 112618 $e 20190607 $i 1872-7905 $m Journal of immunological methods $n J Immunol Methods $x MED00010028
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace